Annexon, Inc. Common Stock (ANNX) Stock Price

ANNXStock
$4.97+134.43%52W
Market Cap$942.21M
P/E
PEG Ratio
Div yield
Beta1.27

ANNX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-11.73%
Price vs S&P 500 (4W)-6.87%
VGM Score59.14

ANNX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.24-$0.28-15.17%(-$0.04)
Q1 2026-$0.30-$0.23+24.01%(+$0.07)
Q4 2025-$0.32-$0.28+11.20%(+$0.04)
Q3 2025-$0.34-$0.37-8.38%(-$0.03)
Q2 2025-$0.36-$0.34+5.96%(+$0.02)

ANNX Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.19
4.12
4.12
4.00

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
ANNXAnnexon, Inc. Common Stock
C$4.97
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Annexon, Inc. Common Stock

Annexon Inc is a clinical-stage biopharmaceutical company developing C1q inhibitors to treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. The company's platform technology targets the classical complement pathway across multiple disease areas affecting the body, brain, and eye. Its pipeline includes product candidates ANX005, ANX007, ANX009, and ANX1502 in development.